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aABSTRACT
Background: Novel formulations and administra-
ion routes of established drugs may result in higher
aximum concentrations or total exposures and po-
entially cause previously unrecognized adverse events.
Objective: This study evaluated the proarrhythmic
otential of hydroxypropyl--cyclodextrin (HPCD)-
diclofenac, a novel injectable diclofenac formulation solubi-
lized with hydroxypropyl--cyclodextrin (HPCD), on
entricular electrical conduction in preclinical and clini-
al models.
Methods: We assessed the effects of diclofenac,
PCD, and HPCD-diclofenac on the human delayed
rectifier potassium channel (IKr) using human embryonic
kidney (HEK) 293 cells transfected with a human ether-
à-go-go–related gene (hERG) using whole-cell patch-
clamp. In a single-dose, active- and placebo-controlled,
4-period crossover, thorough QT in vivo study, 70
healthy volunteers (mean age, 23.3 years; range, 18–49
years; 55.75% male) received HPCD-diclofenac at
7.5- and 75-mg doses, inactive vehicle (placebo), and an
ctive control (moxifloxacin).
Results: In vitro, diclofenac produced no statisti-
ally significant effect on IKr. Significant, non–dose-
dependent effects were observed in the presence of
HPCD or HPCD-diclofenac of similar magnitude
cross the 300-fold dose range of concentrations
ested, suggesting an artifact due to the detergent effect
f HPCD in this in vitro model. In vivo, neither
HPCD-diclofenac dose resulted in QTc prolongation
2 ms (5 ms is the threshold of clinical concern). No
correlation was evident between changes in QTc and
plasma concentrations of diclofenac or HPCD. Con-
firming study sensitivity, moxifloxacin produced a
mean QTc prolongation 10 ms.
646Conclusions: The findings from the present study
suggest that HPCD-diclofenac does not have a dose-
dependent effect in the in vitro hERG assay system and
does not produce proarrhythmic QTc prolongation in
vivo. ClinicalTrials.gov identifier: NCT01812538.
(Clin Ther. 2013;35:646–658) © 2013 Elsevier HS
Journals, Inc.
Key words: cyclodextrin, diclofenac, pain, QT
interval.
INTRODUCTION
Since its introduction in 1974, diclofenac has become the
most commonly prescribed nonselective nonsteroidal anti-
inflammatorydrug (NSAID)worldwide1–3 andhasdemon-
trated a consistent record of efficacy and tolerability in
cute and chronic pain.3,4 Diclofenac can be administered
by multiple routes, although an injectable form is not cur-
rently available in theUnited States. For acute postoperative
pain, the rapid onset of relief of intravenous analgesics is
useful; however, a previous formulation of diclofenac for
injection requires prolonged intravenous infusion times.5 A
recently developed parenteral diclofenac formulation em-
ploys hydroxypropyl--cyclodextrin (HPCD) to solubilize
diclofenac, allowing for low-volume intravenous bolus ad-
ministration. HPCD-diclofenac is well tolerated and effi-
cacious in dental surgery,6,7 abdominal/pelvic surgery,8 and
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D.B. Carr et al.orthopedic surgery9 and shows less platelet inhibition than
etorolac or acetylsalicylic acid.10
Novel formulations, novel routes of administration,
and different infusion rates of marketed drugs may result
in greater maximum observed plasma concentrations
(Cmax) or total exposures (AUC).WhenHPCD-diclofe-
nac is administered by intravenous bolus, Cmax is 4- to
8-fold greater than the Cmax of oral diclofenac. The US
ood andDrug Administration suggests that new formu-
ations of previously approved drugs undergo testing to
etermine their proarrhythmic potential, in accordance
ith the International Conference on Harmonisation of
echnical Requirements for Registration of Pharmaceu-
icals forHumanUse guideline known as E14 (ICHE14).
n particular, proarrhythmic potential is assessed bymea-
uring changes in the duration of the QT interval in a
horough QT (TQT) study, in which ECG interval dura-
ions and wave morphology analysis are conducted on
ata from healthy volunteers. Prolonged repolarization
increased QT interval) may be associated with torsades
e pointes, a polymorphic ventricular tachycardia that
an result in sudden death.11
The studies described here evaluate the proarrhyth-
mic potential of HPCD-diclofenac. The potential for
a product to demonstrate proarrhythmic effects may
be evaluated by in vivo or in vitro experiments. Non-
clinical estimates of arrhythmogenic potential include
in vitro end points of ion channel inhibition or altera-
tion of measured cellular action potential duration.12
As an in vitro screening and predictive tool to assay
potential effects on human cardiac function, human
embryonic kidney (HEK) 293 cells stably transfected
with a human ether-à-go-go–related gene (hERG)13,14
were employed to assess the effect of the study drug on
the human potassium channel current (IKr). The hERG
gene (KCNH2) encodes the  subunit of the potassium
ion channel, which carries the delayed rectifier potas-
sium current involved in the repolarization of the ac-
tion potential in ventricular cardiac myocytes.14 This
study evaluated the individual effects of diclofenac,
HPCD-diclofenac, and HPCD on this potassium
urrent and found that HPCD-diclofenac and
PCD inhibited the hERG current in vitro, while
iclofenac alone did not.
To further investigate this phenomenon in vivo, this
QT clinical trial quantified potential QT/QTc inter-
al prolongations and established the proarrhythmic
otential of HPCD-diclofenac. The findings suggest
hat there was no net effect of HPCD-diclofenac on
May 2013ventricular repolarization in healthy subjects by ECG
analysis. The implications of these results for the use of
in vitro models are discussed.
MATERIALS AND METHODS
hERG Inhibition Assay
Cell Culture
HEK 293 cells stably transfected with the hERG
gene were selected as the test system based on the doc-
umented robustness of the gene expression inHEK 293
cells and the sensitivity of the current to IKr inhibi-
tors.13–16 The HEK 293 cell line was maintained in
minimum essential medium complemented with 10%
fetal bovine serum (Wisent Inc, St. Bruno, Quebec,
Canada), 1% minimum essential medium sodium py-
ruvate, 1%nonessential amino acids, 1%L-glutamine,
1% penicillin/streptomycin, and 400 g/mL G-418
(Geneticin) as the selection agent (all ingredients from
Gibco/Invitrogen, Burlington, Ontario, Canada), and
used between passages 12 and 16. Those cells from
which a gigaohm (G) seal could not be obtained or
that did not generate currents with a distinctive tail
current were eliminated during the equilibration
period.
Reagents
Concentrations of each constituent (diclofenac or
HPCD) of HPCD-diclofenac were selected to reflect
range calculated to exceed the anticipated clinical
herapeutic exposure and provide a safety margin ex-
eeding 30 times the expected maximal therapeutic
lasma concentration. The 4 concentrations of diclofe-
ac sodium (Esteve Quimica, S.A., Barcelona, Spain)
ere 1.58, 15.8, 158, and 474 g/mL. The 4 concen-
rations of HPCD (Roquette America, Inc., Water-
loo, Ontario, Canada) were 14, 140, 1400, and 4200
g/mL. The 4 concentrations of HPCD-diclofenac
ontained 1.58-, 15.8-, 158-, and 474-g/mL diclofe-
nac and 14-, 140-, 1400-, and 4200-g/mL HPCD.
he active control, the IKr inhibitor E-4031 (N-[4-[[1-
[2-(6-methyl-2-pyridinyl)ethyl]-4-piperidinyl]carbon-
yl]phenyl]methane sulfonamide dihydrochloride anhy-
drous, Sigma-Aldrich Co LLC, St. Louis, Missouri),
was used at 500 nM.
The internal pipette solution was composed of
140-mM KCl, 1.0-mM MgCl2, 4.0-mM Mg-ATP,
5.0-mM EGTA, 10-mM HEPES, and 10-mM sucrose,
pH 7.4 0.05. The hERG external solution was com-
posed of 140.0-mM NaCl, 5.0-mM KCl, 1.8-mM
647
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Clinical TherapeuticsCaCl2, 1.0-mM MgCl2, 10.0-mM HEPES, and
10.0-mM dextrose, pH 7.3  0.05. Diclofenac and
PCD stock solutions were prepared in hERG exter-
nal solution. HPCD-diclofenac solution was made by
ombination of the appropriate volumes of diclofenac
tock solution and HPCD stock solution.
Procedure
The whole-cell patch-clamp technique was used to
functionally evaluate drug interactions with the ionic
channels.17 HEK 293 cells plated onto 35-mm petri
dishes were washed twice with 1 mL of hERG external
solution followed by the addition of 2 mL of hERG
external solution. The petri dish was mounted on the
stage of an inverted phase contrast microscope and
maintained at constant temperature (35°C  2°C). A
borosilicate glass micropipette filled with the internal
pipette solution was positioned above a single cell us-
ing an Eppendorf PatchMan micromanipulator (Ep-
pendorf Canada, Mississauga, Ontario, Canada). The
micropipette was lowered to the cell until a close con-
tact was achieved. The G-range membrane-pipette
seal was then created by applying a slight negative pres-
sure (resistances were measured using a 5-mV square
pulse). Cell capacitance was immediately measured to
evaluate cell surface area, using a conversion factor of
1 pF/m2. This cell surface area was later used to cal-
culate net current density.
All currents were recorded following analog filter-
ing using a 4-pole Bessel filter (Frequency Devices,
Haverhill, Massachusetts) set at 1 kHz. Through the
computer-controlled amplifier, the cell was depolar-
ized to a maximum value of 25 mV, starting at 5
mV, in 10-mV increments, for 2 seconds each. The
membrane potential was then returned to55 mV for
2 seconds, and finally repolarized to the holding poten-
tial of 60 mV. This allowed the channels to go from
activated to inactivated mode, and back to activated
mode, to measure robust tail currents. All K selective
currents passing through hERG channels were re-
corded using Axopatch-1D or Axopatch 200B ampli-
fiers and digitized with Digidata 1322A or 1440A
AD-DA interfaces (Axon Instruments Inc, Foster City,
California, nowMolecular Devices Inc). The recording
of the cell current started 500 ms before cell depolar-
ization to5/15/25mV and lasted for 500ms after
the cell had been repolarized to 60 mV.
After baseline recordings were obtained, the in-
creasing concentrations of diclofenac, HPCD, or
648HPCD-diclofenac were added in 20-L aliquots di-
rectly to the experimental chamber and were allowed
to disperse through a closed-circuit perfusion system
using a mini-peristaltic pump (MP-1, Harvard Instru-
ments, Holliston, Massachusetts). Exposure times for
each concentration were limited to 2.5 to 5 minutes.
Following the recording of currents in the presence of
all concentrations of diclofenac, HPCD, or HPCD-
diclofenac, a flow-through perfusion system was used
to wash out the test article and obtain postexposure
hERG currents in the same manner as previously de-
scribed. Finally, an aliquot of E-4031 (final concentra-
tion, 500 nM) was added after the washout recordings
to verify the sensitivity of the system.
The hERG currents generated by heterologous ex-
pression systems such as HEK 293 cells are known to
run down over long periods of recording. Therefore,
parallel experiments were run in the absence of diclofe-
nac, HPCD, or HPCD-diclofenac and in the pres-
nce of the solvent to correct for the time-dependent
ecrease in current density, known as current
undown.
Statistical Analysis
The correction for the time-dependent decrease in
current density involved averaging the changes in cur-
rent density associated with time and solvents, and
multiplying the “test-article” results with the resulting
correction factor. All results appearing in this report
have been corrected for the effect of the vehicle and for
time-dependent changes in current density.
hERG current amplitudes are expressed as current
density (in nanoamperes/picofarad [nA/pF]) to correct
for variations in cell size within the population of cells
used for this study. Currents were analyzed using the
Clampfit 10.0 module of the pClamp 10.0 software
(Axon Instruments Inc).
The results obtained in the presence of each concen-
tration were expressed as net current density, normal-
ized against current density measured in baseline
conditions.
The amplitude of the IKr tail current was calculated
as the difference between the average current recorded
before the depolarizing pulse to15 mV and the max-
imum transient current recorded at the beginning of
the repolarizing pulse to 55 mV. Paired t tests were
performed to determine the statistical significance of
the differences in current density obtained before and
after the exposure of the cells to the test article. Signif-
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D.B. Carr et al.icance was set at P  0.05, where P is the probability
that the difference in current density levels is due to
chance alone.
TQT Study
Subjects
To calculate the appropriate sample size for this
study, an SD of 10 ms () for mean QTc prolongation
as assumed for the primary end point, and a maxi-
um difference of no more than 3 ms () was assumed
or the active arm compared with placebo. A sample
ize of 64 evaluable subjects was selected to provide an
verall power of 85% for the primary hypothesis using
he following formula18:
N 22Z1	Z1  1⁄k2 ⁄ 10
2,
where k is the number of assessments, and Z1 –  and
Z
(1 – )
1/k are normal-distribution quantiles. The calcu-
ation assumed  to be equal to 0.05, and 1 –  was
aken to be 0.85.
To allow for the possibility of 10% dropouts, 72
ubjects were to be randomized to receive study drug.
Following approval by the institutional review
oard (PRACS Institute, Fargo, North Dakota), writ-
en informed consent was obtained from 171 screened
ealthy subjects. The 72 subjects, approximately equal
umbers of men and women, were to be enrolled and
dmitted to the clinical research unit for a period of 13
ays. Eligible subjects were required to be healthy men
r women, 18 to 50 years of age, with a body mass
ndex (BMI) between 18 and 30 kg/m2, in good general
ealth, and having a normal or non–clinically signifi-
ant ECG at screening (QTc interval 450 ms in men
nd 470 ms in women, consistent sinus rhythm, no
linically significant conduction disorders, PR interval
etween 120 and 230 ms, heart rate [HR]100 beats/
in [bpm] and40 bpm, QRS interval110 ms, and
T intervals that could be consistently analyzed). Sub-
ects were also required to have normal or non–clini-
ally significant results of physical examination, labo-
atory screening, and vital-sign assessment and the
bsence of any systemic illness, history of cardiac dis-
ase, or a family history of QT prolongation that
ould increase the risk of participation in this study.
emale subjects were also required to have a negative
regnancy test and either remain sexually abstinent or
se an appropriate form of birth control during the
ourse of study participation. p
May 2013Exclusion criteria consisted of a history or presence
f significant cardiovascular, pulmonary, hepatic, re-
al, hematologic, gastrointestinal, endocrine, immu-
ologic, dermatologic, neurologic, or psychiatric dis-
ase; history of invasive cancer within the previous 5
ears (excluding nonmelanoma skin cancers); history
f hypersensitivity or allergy to the quinolone class of
ntibiotics, to diclofenac or other NSAIDs, or to
PCD or other excipients in HPCD-diclofenac
monothioglycerol, sodium hydroxide, hydrochloric
cid, and water for injection); a significant clinical lab-
ratory test or ECG abnormality at screening; history
r presence of alcoholism or drug abuse within 2 years
rior to the study; history of clinically significant syn-
ope; and use of any prescription or over-the-counter
edications, including topical medications, vitamins,
nd herbal or dietary supplements/remedies (eg, St
ohn’s wort or milk thistle) within 14 days of study
dmission. Subjects with a history of additional risk
actors for torsades de pointes (eg, heart failure, hypo-
alemia, history of drowning survival, family history
f long QT syndrome, family history of short QT syn-
rome, family history of unexplained early sudden
eath) were also precluded from study participation.
Procedure
The TQT study was of randomized, single-dose,
comparative, active- and placebo-controlled, 4-way
crossover design and evaluated the effect of HPCD-
diclofenac on QTc intervals in healthy subjects. There
was 1 period of confinement of 13 days, with subjects
admitted to the clinic on study day2 (2 days prior to
the start of dosing) and discharged on study day 11
(day 11 after first dosing). All subjects completed a
follow-up visit 7  3 days after clinic discharge.
The effect of HPCD-diclofenac 37.5 mg on the
Tc interval was compared to that of placebo (normal
aline). A 75-mg dose of HPCD-diclofenac was also
valuated because it was the highest dose tested in the
linical program. The active control, moxifloxacin hy-
rochloride 400 mg, was used to validate the trial and
o demonstrate the expected QTc response in the sub-
ects. The expected effect of the 400-mg moxifloxacin
ablet on the QTc intervals was a mean increase of5
s, which is the effect that represents the threshold of
egulatory concern.
Subjects received a single bolus dose of HPCD-
diclofenac 37.5 mg IV, HPCD-diclofenac 75 mg IV,
lacebo (normal saline) IV, and moxifloxacin tablet
649
d
i
H
p
d
a
d
t
e
t
m
m
i
t
H
t
w
e
c
t
p
t
r
I
s
c
w
a
i
h
l
a
b
w
w
v
h
n
s
m
a
p
T
a
i
d
w
s
t
2
d
i
p
c
t
m
o
d
i
f
u
Q
Clinical Therapeutics400 mg PO (active control) once, in accordance with
the randomization sequence, during the 13-day admis-
sion, with a 72-hour washout period between each
dosing. Subjects were dosed on study days 1, 4,
7, and10. Study days2 and3,5 and6, and
8 and 9 were designated as study drug washout
ays. On each day of dosing, 12-lead ECGs for QT-
nterval analysis were acquired from a continuous
olter recording flashcard at selected nominal time
oint intervals: 1.5, 1.0, and 0.5 hours (pre-
ose); 5, 10, 15, and 30 minutes (2-minute window);
nd 1, 2, 4, 6, 8, 12, and 23.5 hours (5-minute win-
ow). The ECGs were 15 seconds in duration and ex-
racted in triplicate. Time-matched ECGs were also
xtracted in triplicate for the same 24-hour period on
he day prior to dosing. The QT-interval measure-
ents were obtained by averaging 3 to 5 QT intervals
easured from rawwaveforms in a single lead, primar-
ly lead II.
Subjects were to be kept resting in the supine posi-
ion for 10 minutes before the intense cluster of ECG
olter recordings at the nominal time points during
he first hour postdose. After the first hour, the subjects
ere to resume supine resting for 10 minutes prior to
ach ECG nominal time point. Subject ambulation, in-
luding use of toilet facilities, was prohibited during
he 10 minutes prior to each of the ECG nominal time
oints. Throughout the Holter recording procedure,
he use of cellular phones, handheld music players,
eading material, or computer devices was prohibited.
n addition, subjects were not permitted to engage in
trenuous exercise while under observation at the
linic.
Because meals can prolong the QT interval, subjects
ere kept to fasting on study days 1, 1, 4, 7,
nd 10 during the hours of frequent ECG collection
n the morning. A midday meal could be given 4 to 6
ours postdose and concluded within 30 minutes, al-
owing for 1.5 hours before the next ECG acquisition
t 6 hours postdose. The evening meal was scheduled
etween 8 and 12 hours postdose. Identical lunches
ere served to each subject on all dosing days. On
ashout days, standard meals and beverages were pro-
ided as per the clinic’s usual policy, and subjects could
ave these meals at their preferred times.
Blood was drawn from each subject for the determi-
ation of diclofenac, HPCD, and moxifloxacin phar-
macokinetic properties at time 0 (predose), and 5,
65010, 15, 20, and 30 minutes and 1, 1.5, 2, 2.5, 3, 4, 6, 8,
12, 18, and 23.5 hours after dosing.
Statistical Analysis
All clinical data were analyzed using the SAS System
version 8.2 or higher (SAS Institute Inc, Cary, North
Carolina). The primary ECG end point was the time-
matched active drug–placebo difference in baseline-ad-
justed QTc interval (predose baseline-adjusted) using
the Fridericia correction formula (QTcF) evaluated at
the time point at which the maximum mean baseline-
and placebo-adjusted QTcF was observed for each ac-
tive treatment arm. The QTcF was defined as QT/
RR0.333, where RR is the time elapsing between 2 con-
ecutive R waves on the ECG.
For measurements at each time point, an ANOVA
odel for a crossover design was fit to the baseline-
djusted QTcF data, including effects for treatment,
eriod, and subject, with subject as a random effect.
he time point at which the time-matched placebo-
nd baseline-adjusted QTcF had the highest mean was
dentified separately for each of the HPCD-diclofenac
ose arms and the moxifloxacin arm. In accordance
ith ICH E14, the study was deemed to have demon-
trated no clinically meaningful QT interval prolonga-
ion if the 1-sided 95% upper confidence limits for the
HPCD-diclofenac doses were 10 ms.
The washout period between treatment arms was 2
ays to prevent treatment carryover effects from 1 dos-
ng period to the next. This was tested formally for the
rimary end point only by the addition of a 1-period
arryover effect (effect of treatment in prior period) to
he ANOVA crossover model with effects for treat-
ent, period, and subject (random effect). The carry-
ver for the first period was defined as zero.
As secondary end points, time-matched active
rug–placebo difference in baseline-adjusted QTc
ntervals were evaluated using the Bazett correction
ormula (QTcB), which has been more frequently
sed in previous literature. The QTcB was defined as
T/RR0.5.
The QTcB was evaluated at the time point at which
the maximum mean baseline- and placebo-adjusted
QTcB was observed for each active treatment arm.
A population-specific regression model was con-
structed for the QT correction (QTcP) at the time
point(s) at which the maximum mean baseline- and
placebo-adjusted QTcB and QTcP, respectively, were
observed for each active treatment arm. For this adjust-
Volume 35 Number 5
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D.B. Carr et al.ment, all of the paired drug-free QT and RR interval
measurements taken on study day1 for all subjects in
the trial were plotted (QT vs RR). A linear regression
of the QT and RR relationship was modeled, and the
slope estimate from this regression model,m,was used
n the HR correction of the QT interval. The QTcPwas
erived as QT  m(1 – RR).
Relationships between the placebo-corrected changes
rom baseline in QTcF, QTcB, and QTcP (QTcF,
QTcB, and QTcP, respectively) and the plasma
oncentrations of diclofenac and HPCD were also
xplored graphically using SigmaPlot version 11.0
Systat Software, Inc, Chicago, Illinois). PK parameters
ere calculated using noncompartmental analysis.
max and Tmax were taken directly from the data. The
erminal elimination rate constant, z, was calculated
s the negative slope of the terminal log-linear segment
f the plasma concentration–time curve. The t1⁄2 value
as calculated as 0.693/. AUC0–t was calculated us-
ng the linear trapezoidal method and extrapolated to
nfinity using the formula AUC0–  Ctf/z, where Ctf
is the last measurable concentration. Total plasma
Table I. Effects of injectable diclofenac* and HPCD
unless otherwise noted).
Corrected Normalized
Current Density
Diclofenac
Mean (SEM) P
1	 1.159 (0.107) 0.19
10	 1.289 (0.188) 0.18
100	 0.914 (0.128) 0.53
300	 0.941 (0.095) 0.56
Washout 1 1.136 (0.22)§ 0.57
E-4031 0.301 (0.039)§ 0.02‡
Washout 2 0.229 (0.099)¶ 0.83
hERG 
 human ether-à-go-go–related gene; HPCD 
 hyd
*Diclofenac 1	 
 1.58 g/mL.
†HPCD 1	 
 14 g/mL.
‡Statistical significance at P  0.05 versus current density r
active control (E-4031) were compared to the currents rec
second washout period were compared to the current mea
§n 
 5.
n 
 6.
¶n 
 3.
#n 
 4.clearance (CL) was calculated as Dose/AUC, and ter- n
May 2013minal volume of distribution (Vz) was calculated as
ose/(z 	 AUC).
RESULTS
hERG Channel Assay
Diclofenac, at concentrations up to 474 g/mL,
aused no significant inhibition of the hERG current
ecorded by patch-clamp from HEK 293 cells stably
ransfected with hERG (Table I). None of the diclofe-
ac concentrations tested significantly inhibited the
ERG current compared with the baseline current den-
ity measured at I15 (n 
 7).
Testing of varying concentrations of the formula-
tion vehicle, HPCD, produced statistically significant
but non–dose-dependent effects on hERG current. The
4 HPCD concentrations tested (14, 140, 1400, and
4200 g/mL) produced similar effects in the test sys-
em, causing, respectively, 22.5%, 39.3%, 43.5%, and
6.5% inhibition of the hERG current density for I15
(n 
 7).
HPCD-diclofenac produced effects similar to
those observed with the vehicle HPCD, causing sig-
ERG current density (N
 7 responsive cells patched
HPCD HPCD-Diclofenac
ean (SEM) P Mean (SEM) P
75 (0.042) 0.002‡ 0.807 (0.038) 0.14
07 (0.058) 0.001‡ 0.547 (0.051) 0.002‡
65 (0.047) 0.0001‡ 0.522 (0.066) 0.001‡
35 (0.059) 0.001‡ 0.590 (0.068) 0.018‡
71 (0.135) 0.019‡ 0.397 (0.181) 0.002‡
08 (0.034) 0.007‡ 0.154 (0.045) 0.052
91 (0.052) 0.082 0.053 (0.030)# 0.007‡
opyl -cyclodextrin.
d after the baseline condition. Currents recorded after the
after the first washout period; currents measured after the
following exposure of the cells to the active control.† on h
M
0.7
0.6
0.5
0.6
0.5
0.1
0.1
roxypr
ecorde
orded
suredificant and dose-independent current inhibition. The
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Clinical Therapeutics3 highest concentrations of HPCD-diclofenac tested
espectively caused 45.3%, 47.8%, and 41% inhibi-
ion of the hERG tail current density (n 
 7). The IKr
selective inhibitor E-4031 induced respective decreases
of 73.5%, 81.1%, and 61.2% compared with the av-
eraged I15 tail current remaining after diclofenac,
PCD, or HPCD-diclofenac washout. The inhibi-
tory effect of E-4031 was consistent with published
potency and was irreversible. The observed irrevers-
ibility of this inhibition was consistent with previous
observations.13
TQT Study
Of the 171 screened subjects, 74 were randomized
and 70 received study drug. Four randomized subjects
were withdrawn just prior to dosing, as 2 withdrew
consent, 1 had an abnormal vital signs assessment at
baseline, and 1 had an abnormal laboratory result at
baseline. Among the 70 subjects who completed the
study, 39 were male (55.7%) and 31 were female
(44.3%). The treatment-sequence groups were compa-
rable with respect to all demographic and baseline
Table II. Baseline- and placebo-adjusted QTcF at m
clofenac or moxifloxacin in each active-treat
HPCD-D
37.5
Maximum mean, ms
Nominal time after dosing 1
Adjusted mean* 1
SE 1
90% CI* 0.45
At subject-specific Tmax of diclofenac
Adjusted mean* 0
SE 1
90% CI* 2.27
At subject-specific Tmax of HPCD
Adjusted mean* 0
SE 1
90% CI* 2.13
HPCD 
 hydroxypropyl -cyclodextrin; QTcF 
 Fridericia
*Adjusted mean (baseline-adjusted QTcF for active – baselin
an ANOVA model with effects for subject, period, and treacharacteristics. The mean age was 23.3 years (range, l
65218–49 years), and the mean BMI was 24.7 kg/m2
(range, 18.3–29.8 kg/m2).
Evaluation of the primary ECG end point indicated
hat exposure to HPCD-diclofenac at the 37.5- and
5-mg doses produced no clinicallymeaningfulQT inter-
al prolongation. Administration of HPCD-diclofenac
did not cause mean QTc prolongation beyond 5 ms, the
threshold of regulatory safety concern (Table II). The
time points at which the time-matched placebo- and
baseline-adjusted QTcF had the highest means were 1
hour postdosing in both the HPCD-diclofenac 37.5-
and 75-mg treatment arms and 4 hours postdosing in
the moxifloxacin 400-mg treatment arm. The upper
limits of 1-sided 95% upper confidence limits, equal to
the 90% CI boundary, were 3.68 and 3.42 ms with
HPCD-diclofenac 37.5 and 75 mg, respectively. In
addition, mean QTc prolongation was 5 ms when
measured at subject-specific Tmax of diclofenac and
HPCD. The upper limits of the 90% CI of the ad-
justed mean for each HPCD-diclofenac dose at the
max of diclofenac and the Tmax of HPCDwere all2
s, providing further evidence that QTcF is not pro-
m mean and subject-specific Tmax with HPCD-di-
arm (n 
 70 per arm).
enac HPCD-Diclofenac
75 mg IV
Moxifloxacin
400 mg PO
1 h 4 h
1.36 10.62
1.25 1.28
68 0.70 to 3.42 8.50 to 12.73
0.22 —
1.18 —
55 2.17 to 1.74 —
0.04 —
1.18 —
73 1.91 to 1.99 —
ted QT interval.
sted QTcF for placebo), SE, and 90% CI were obtained from
, with subject as a random effect.aximu
ment
iclof
mg IV
h
.62
.25
to 3.
.36
.16
to 1.
.20
.17
to 1.
-correc
e-adju
tmentonged by HPCD-diclofenac. The moxifloxacin
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D.B. Carr et al.group had a mean maximum effect of 10.62 ms, and
the lower limit of the 90% CI (8.50–12.73) was 5
ms, establishing the study’s sensitivity to detect a
meaningful drug-induced prolongation of QTc. Ad-
justed means of the time-matched active drug–placebo
differences in baseline-adjusted QTcF with the 37.5-
and 75-mg doses of HPCD-diclofenac and moxi-
oxacin 400 mg are presented in Figure 1.
The results usingQTcBandQTcPwere comparable to
he primary end point (QTcF). The time-matched active
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Figure 1. Adjusted means of the time-matched active
corrected QT interval (QTcF). Overlays of
concentrations (open symbols) of (A) dic
following administration of intravenous H
control).rug–placebo difference in baseline-adjusted QTc inter- Q
May 2013al using QTcB and QTcP at the time point of the maxi-
um mean baseline- and placebo-adjusted QTcB and
TcP, respectively, were similar. The adjusted mean
TcB (baseline – mean QTcB) was 0.83 ms with
PCD-diclofenac 37.5 mg, 0.99 ms with HPCD-di-
lofenac 75 mg, and 11.92 ms with moxifloxacin. The
ower limit of the 90% CI of the adjusted mean QTcB
ith moxifloxacin was 5 ms, as expected, again vali-
ating the assay sensitivity. Using the population-derived
inear regression line and the slope of the line to calculate
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Clinical Therapeuticswas 1.80 ms with HPCD-diclofenac 37.5 mg, 1.57 ms
ith HPCD-diclofenac 75 mg, and 10.75 ms with
oxifloxacin. With both corrective methods, the upper
imit of the 90% CI of the adjusted mean of each
PCD-diclofenac dose was10ms, indicating no clin-
ically meaningful QTcB orQTcP prolongation. Absolute
QTcF values of450msoccurredwith similar frequency
ith placebo and HPCD-diclofenac, and there were no
changes of30 ms in these groups.
Subset evaluations of the male and female subpopula-
ions were consistent with the overall results. Applying
he primary analysis forHPCD-diclofenac, therewas no
vidence of QTcF prolongation in the men or women. In
hemen (n
39), the adjustedmeanQTcFswere 1.76ms
ithHPCD-diclofenac 37.5mg, 0.51mswithHPCD-
iclofenac 75 mg, and 9.15 ms with moxifloxacin. In the
omen (n 
 31), the corresponding adjusted mean
TcFs were 1.52, 3.69, and 12.44 ms. In both the men
ndwomen, the upper limit of the 90%CIof the adjusted
ean with each HPCD-diclofenac dose was 10 ms,
ndicating no clinically meaningful QTcF prolongation.
None of the male subjects (n 
 39) had a mean QTcF
alueof450msoran increaseof30ms frombaseline at
ny timepoint.Values of470mswere considerednormal
n women. Mean QTcF values between 470 and 480 ms
ere observed in 1 female subject following placebo and
Table III. Mean pharmacokinetic properties of diclofe
unless otherwise noted). Values are arithm
Parameter
HPCD-Diclofenac 37
Diclofenac H
Cmax, ng/mL 6493 (1363) 4957
Tmax, h* 0.083
AUC0–t, h · ng/mL 1984 (399) 5957
AUC0–, h · ng/mL 2017 (397)
† 6035
z, h
1 0.421 (0.075)† 0.40
t1⁄2, h 1.70 (0.33)
† 1.7
CL, mL/min 299 (57.9)† 95.
Vz, L 43.4 (9.3)
† 14.
z
 terminal elimination rate constant; CL
 total plasma
volume of distribution.
*Median.
†n 
 66.
‡n 
 69.oxifloxacin treatments. One female subject had an in-
654rease frombaselineQTcFbetween30and60ms following
oxifloxacin treatment.
The PK data confirmed that exposures to diclofenac,
PCD, and moxifloxacin were consistent with the
known PK properties of each compound. A summary
of mean the PK properties of diclofenac and HPCD is
resented inTable III. For diclofenac, dose proportion-
lity is evident on examination of these parameters.
ean values of Cmax and AUC0– increased 2-fold be-
tween the 37.5- and 75-mg HPCD-diclofenac doses,
and the mean values for CL, Vz, and t1⁄2 were similar
with both doses. Dose proportionality was also ob-
served for the HPCD PK parameters. The mean val-
ues of Cmax and AUC0– increased 2-fold between the
7.5-mg (333.3-mg HPCD) and 75-mg (666.7-mg
HPCD) HPCD-diclofenac doses, whereas the mean
alues for CL, Vz, and t1⁄2 were similar between the 2
doses. The mean plasma concentrations of diclofenac
and HPCD following intravenous administration of
PCD-diclofenac are presented in Figure 1.
No relationship between QTcF and the plasma
concentration of either diclofenac or HPCD was ap-
parent (Figure 2). Because there was no apparent rela-
tionship between any QTc and the corresponding
plasma concentrations of diclofenac or HPCD, no
nd HPCD measured in thorough QT study (N
 70
ean (SD) unless otherwise noted.
IV HPCD-Diclofenac 75 mg IV
D Diclofenac HPCD
553) 12102 (2146) 99039 (21709)
0.083 0.083
737) 3943 (788) 130497 (27384)
563)‡ 3967 (789) 131163 (27377)
045)‡ 0.389 (0.067) 0.382 (0.059)
23)‡ 1.84 (0.35) 1.86 (0.32)
.5)‡ 304 (62.1) 88.2 (17.3)
5)‡ 48.1 (11.2) 14.1 (3.2)
nce; HPCD
 hydroxypropyl -cyclodextrin; Vz
 terminalnac a
etic m
.5 mg
PC
0 (11
0.083
1 (10
5 (10
4 (0.
4 (0.
1 (18
3 (3.
clearaPK/PD models were fitted to the data.
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HPCD-diclofenac was well tolerated in this
healthy adult population. The prevalences of treat-
ment-emergent adverse events (TEAEs), defined as any
events not present before exposure to the study drug or
any events already present that worsened in either in-
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Figure 2. A. Relationship between placebo-corrected
(QTcF) and plasma concentrations o
(HPCD) after intravenous administration
(HPCD 333.3 and 666.7 mg, respectivelytensity or frequency following exposure to study drug,
May 2013were 8.6% with HPCD-diclofenac 37.5 mg and with
lacebo, 10.0% with HPCD-diclofenac 75 mg, and
12.9% with moxifloxacin. The most frequent TEAEs
were nervous system disorders (ie, dizziness and head-
ache), followed by administration-site conditions (in-
cluding injection-site pain and hematoma). The fre-
ntration (ng/mL)
000 15,000 20,000
ation (ng/mL)
00 150,000 200,000
ge from baseline in Fridericia-corrected QT interval
diclofenac and (B) hydroxypropyl -cyclodextrin
CD-diclofenac 37.5 (triangles) and 75 mg (circles)
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Clinical Therapeuticsboth HPCD-diclofenac doses, 5.7% with moxifloxa-
in, and 2.9%with placebo. The frequencies of admin-
stration-site conditions were 2.9% with HPCD-di-
clofenac 37.5 mg, 4.3% with HPCD-diclofenac 75
mg, 2.9% with moxifloxacin, and 5.7% with placebo.
No treatment-related TEAEs were reported with pla-
cebo, whereas the frequencies were 2.9% with
HPCD-diclofenac 37.5 mg, 4.3% with HPCD-di-
clofenac 75 mg, and 7.1% with moxifloxacin. The
most frequent treatment-related TEAEs were dizziness
and nausea, which were reported only with HPCD-
diclofenac 75 mg (1.4% and 2.9%, respectively) and
moxifloxacin (5.7% and 4.3%, respectively).
At baseline and study completion, all mean hema-
tology and chemistry measurements were within nor-
mal limits. The most notable shifts were decreases in
hematocrit, hemoglobin, neutrophils, and red blood
cell count, likely related to repeated blood draws dur-
ing the study.
No deaths, discontinuations, or serious adverse
events were reported. None of the subjects reported
experiencing episodes of ventricular tachycardia, fi-
brillation, syncope, or seizure.
DISCUSSION
Our results demonstrate the tolerability of HPCD-
diclofenac in terms of an absence of proarrhythmic
QTc prolongation, while highlighting some concerns
and caveats related to the in vitro experimental system
used to evaluate that risk. The in vitro studies indicate
that diclofenac causes no significant inhibition of the
hERG channel current recorded by patch-clamp from
HEK 293 cells, providing a safety margin exceeding
30 times the anticipated plasma concentration of
HPCD-diclofenac. In the presence of HPCD alone,
the hERG current was significantly inhibited, but in a
dose-independent manner. The inhibition of the hERG
current by HPCD-diclofenac correlates closely with
hat following exposure to HPCD alone. Therefore,
he authors conclude that the effect observed for
PCD-diclofenac resulted from the non–dose-de-
pendent effect of HPCD with the hERG channel.
The excipient HPCD is a cyclic, glucose-derived
ligomer consisting of linked a-1 A-glucose units used
o enhance the solubility of diclofenac.19 These glucose
ligomers form a cone-like cavity into which poorly
ater-soluble compounds may enter, forming a water-
oluble complex. Cyclodextrins are used to solubilize
ver 35 drugs on the market today.20 Advantages of t
656solubilizing with HPCD include a reduction in dosing
olume, reduction in irritation from the high or low pH
r the use of organic solvents needed for solubilization,
nd avoidance of direct venous irritation from the drug
tself. HPCD has been employed to enhance the sol-
ubility of poorly soluble drugs such as the marketed
antifungal itraconazole, a novel formulation of propo-
fol, and several other intravenous, oral, suppository,
and eye-drop formulations.20–22
The lack of dose response in the hERG blockade for
both HPCD-diclofenac and HPCD suggests that the
echanism is a nonspecific, detergent-like artifact of
PCD in this in vitro testing system. Supporting this
hypothesis, Mikhail et al23 reported a significant inhi-
ition of hERG currents when measured by patch-
lamp at 37°C on stably transfected HEK 293 cells in
he presence of cyclodextrins. The nonspecific effect on
ERG by HPCD has been attributed to the an inter-
action of HPCD with lipid rafts in the cell mem-
rane,23,24 which is supported by data indicating that
other ion channels exhibit cholesterol-dependent activ-
ity.25 Nonetheless, because hERG channel blockade
s not perfectly correlated with in vivo effects on the
T interval,12,26 a thorough QT (TQT) study was
erformed.
The data from the TQT study demonstrate that 37.5
r 75 mg HPCD-diclofenac is not likely to cause
proarrhythmic QTc prolongation. In general, women
are at greater risk for torsades de pointes27; however,
results from the present study indicated that women
were not more likely to show a prolonged QT interval
compared with men. The different corrections for HR
for the QT interval were all in agreement in the present
results. The Fridericia correction (QTcF) is more fre-
quently used at present, whereas the Bazett correction
(QTcB) has been used historically in the literature, al-
though the latter may not correct as accurately for ex-
treme values. The population-based estimations of the
QT interval (QTcP) were also in accordance with
QTcF and QTcB. The PK data from the study con-
firmed that subjects were exposed to diclofenac and
HPCD as expected, but no apparent relationship be-
tween the placebo-corrected cha nge from baseline in
QTcF, QTcB, or QTcP and the plasma concentration
of either diclofenac or HPCD was observed.
Thus, the results of the TQT study further support
he conclusion that the hERG effect of HPCD is an
rtifact of the membrane-testing system employed, as
here was no indication that HPCD-diclofenac
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D.B. Carr et al.lengthened the QT interval. These results are consis-
tent with those from other postmarketing clinical stud-
ies of diclofenac, which have shown no evidence of
torsades de pointes.3,4,6,7
Preclinical models are increasingly used during the
drug development process to assess arrhythmogenicity,
and are generally well correlated with results from
TQT studies.26 However, our results showing the non-
specific effect of cyclodextrins highlight the limits in-
herent in simplified in vitro systems. Poorly soluble
drugs present a particular problem, as other types of
carrier, such as organic solvents or nonionic surfac-
tants, can also interfere with the hERG potassium cur-
rent.24 The data from these studies suggest not only
hat controls should be carefully selected when testing
ther drug formulations that use cyclodextrins as sol-
bilization vehicles in this model system, but also that
ther in vitro models should be considered and that
ultiple methods should be employed.24,26
CONCLUSION
The findings from the present study suggest that
HPCD-diclofenac has no dose-dependent effect in the
in vitro hERG assay system and does not produce
proarrhythmic QTc prolongation in vivo.
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